Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease

Presenter: Matthew J. Matasar

Despite a growing therapeutic arsenal to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), outcomes remain poor. Only approximately half of patients with this disease are eligible to receive curative autologous stem cell transplant, and of those, only half will be cured. Moreover, for patients who are transplant-ineligible, there are few effective options. Dr. Matthew J. Matasar discussed the current unmet needs in the treatment of patients with R/R DLBCL, treatment strategies in the second- and third-line settings, and emerging therapeutic options.

Disclosures: Dr. Matasar has disclosed receiving consulting fees from Bayer HealthCare, Daiichi-Sankyo Co., Genentech, Inc., Juno Therapeutics, Inc., Merck & Co., Inc., Roche Laboratories, Inc., Rocket Medical, Seattle Genetics, Inc., Takeda Pharmaceuticals North America, Inc., and Teva Pharmaceutical Industries Ltd.; receiving grant/research support from Bayer HealthCare, Genentech, Inc., GlaxoSmithKline, IGM Biosciences, Immunovaccine Technologies, Janssen Pharmaceutica Products, LP, Pharmacyclics, Roche Laboratories, Inc., Rocket Medical, and Seattle Genetics, Inc.; receiving honoraria from Bayer HealthCare, Genentech, Inc., GlaxoSmithKline, Immunovaccine Technologies, Janssen Pharmaceutica Products, LP, Pharmacyclics, Roche Laboratories, Inc., Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and having ownership/partnership/principal in Merck & Co. Inc.

Correspondence: Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: matasarm@mskcc.org
  • 1.

    Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:18001808.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Herrera AF, Ogbu U, Ku G, Chuo CY. Real-world bendamustine use in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) [abstract]. Hematol Oncol 2019;37(Suppl 2):428429. Abstract 388.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:41844190.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:34903496.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    van Imhoff GW, McMillan A, Matasar MJ, et al. ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 2017;35:544551.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Lu T, Gibiansky L, Li X, et al. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2020;61:29052914.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978988.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Locke FL, Neelapu SS, Bartlett NL, et al. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) [abstract]. Presented at the 2017 AACR Annual Meeting; April 1–5, 2017; Washington, DC. Abstract CT019.

    • Search Google Scholar
    • Export Citation
  • 9.

    Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:4556.

  • 10.

    Abramson JS, Palomba ML, Gordon LI, et al. CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001) [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 7513.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 2020;4:46694678.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790800.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Matasar MJ, Cheah CY, Yoon DH, et al. Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts [abstract]. Blood 2020; 136(Suppl 1):4546. Abstract 2096.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 447 447 447
PDF Downloads 287 287 287
EPUB Downloads 0 0 0